Léčba maligního mezoteliomu pleury v České republice
2019
Malignant pleural mesothelioma (MPM) is the most frequent
primary tumor of this anatomical structure. It is usually
caused by exposure to asbestos and the incidence continues to
rise despite the fact that work with asbestos is banned in
European countries. Presented is a set of data on consecutive
patients treated with standard first-line cisplatin/pemetrexed
chemotherapy in Czech centers. Another sample comprised
patients receiving second-line pemetrexed therapy. Data from
2008-2018 were analyzed at the Institute of Biostatistics and
Analyses in Brno. The study included 249 and 35 patients
receiving first- A nd second-line therapy, respectively. There
were 66 females and 183 males with a mean age of 64 years.
Occupational and non-occupational exposure to asbestos was
confirmed in 58 and 23 cases, respectively; no exposure was
found in 168 patients. The most common histological types were
epithelioid MPM in 167 patients, mixed in 26 and sarcomatoid in
16 patients; no histological type was determined in 40
subjects. There were 23 patients with TNM stage I, 41 with
stage II, 64 with stage III and 115 with stage IV. For the
entire sample, the median progression-free survival was 9.6
months and median overall survival (OS) was 20.1 months.
Patient survival was affected by the TNM stage and histological
type of the tumor. For the second-line therapy, the median OS
was 9.9 months. It may be concluded that the prognosis of
patients with malignant mesothelioma is still not satisfactory
and new treatment options need to be sought. Comments on
outcomes of some recent studies are added. © 2019 Trios spol.
s.r.o.. All rights reserved.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI